Clinical trials: Cardiac Ischemia
Coronary Arteriosclerosis
Support C Post-Market Registry
To collect post marketing surveillance data on consecutive patients with coronary heart disease intended to be or treated by the drug eluting Support C PTCA balloon catheter when used according to the Instructions for Use.
- Trial name
- NCT06678490
- Where
- 12 sites in Czechia, Germany and 2 more
- Volunteers
- 282 people
- Sponsor
- OrbusNeich
Coronary Occlusion
Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries
The CiTop™ guidewire Coronary study is a feasibility open label study, to evaluate the safety and efficacy of the CiTop™ Guidewire for crossing chronic total occlusion in Coronary arteries.
- Trial name
- NCT00618020
- Testing
- CiTop(tm) Guidewire
- Where
- India
- Volunteers
- 10 people
- Sponsor
- Ovalum
CAD - Coronary Artery Disease
Angiogram Based Fractional Flow Reserve FFRangio - A Validation Study
In the present study we aim at validating the computation of FFRangio values from the angiogram by comparing them to measured wire-based FFR values, in a larger scale and in a completely blinded manner.
- Trial name
- NCT03005028
- Where
- Israel
- Volunteers
- 184 people
- Sponsor
- CathWorks Ltd.
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome.
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00684203
- Testing
- Vorapaxar, Aspirin, Clopidogrel
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Myocardial Infarction
Determining the Optimal Cut-off Point of PEA by Corsens Device for Discriminating Between MI and Non-MI Subjects
Acute Myocardial Infarction (MI) is still the leading cause of death in the western world. Early warning (chest pain) signs of an acute MI are often misinterpreted and disregarded.
- Trial name
- NCT02723851
- Testing
- Corsens
- Volunteers
- 76 people
- Sponsor
- Corsens Medical LTD
Stable Angina Pectoris
Efficacy and Safety Study of Total Flavonoids of Propolis Dropping Pill to Treat Angina Pectoris
The purpose of this study is to confirm the efficacy and safety of total flavonoids of propolis dropping pill to treat angina pectoris, evaluated by total exercise time of treadmill exercise test.
- Trial name
- NCT01453582
- Testing
- Total Flavonoids of Propolis dropping pill
- Where
- 13 sites in China
- Volunteers
- 478 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.
- Trial name
- NCT01523366
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease
EXCEL Clinical Trial
To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO [for use outside the United States [OUS] only]) in subjects with…
- Conditions
- Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease
- Trial name
- EXCEL (NCT01205776)
- Testing
- Percutaneous Coronary Intervention, CABG
- Where
- United States
- Volunteers
- 1,905 people
- Sponsor
- Abbott Medical Devices
Coronary Heart Disease
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety
- Trial name
- NCT00134940
- Where
- 6 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- Novartis
Hypercholesterolemia
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
The purpose of this study was to evaluate the long-term safety and tolerability of ezetimibe 10 mg once daily co-administered with atorvastatin 10 to 80 mg daily for up to 12 consecutive months in participants with heterozygous…
- Trial name
- NCT03882996
- Testing
- Ezetimibe, Atorvastatin
- Volunteers
- 432 people
- Sponsor
- Organon and Co
Coronary Artery Disease
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial
The purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.
- Trial name
- NCT01496261
- Testing
- Clopidogrel and Aspirin, Fixed dose combination of clopidogrel/aspirin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Stable Coronary Artery Disease, Acute Coronary Syndromes
Coronary Laser Atherectomy Registry From an International Taskforce
This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).
- Trial name
- CLARIT (NCT07348341)
- Testing
- Excimer Laser Coronary Atherectomy (ELCA)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Ceric Sàrl
Myocardial Infarction
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
- Trial name
- ALLSTAR (NCT01458405)
- Testing
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Capricor Inc.
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease
The purpose of this study is to determine if the use of PB127 with cardiac ultrasound assists in the diagnosis or exclusion of coronary artery disease.
- Trial name
- POINT II (NCT00584896)
- Testing
- PB127 for Injectable Suspension
- Where
- 40 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Point Biomedical
Myocardial Infarction
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.
- Trial name
- NCT00877903
- Testing
- Prochymal®
- Where
- 33 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Mesoblast, Inc.
Stable Angina, Ischemic Heart Disease Silent
A Randomized Clinical Evaluation of the BioFreedom™ Stent
The purpose of this study is to demonstrate that a BioFreedom™ Drug Coated Stent is non-inferior to a bare metal stent at one year as measured by the composite safety endpoint of cardiovascular death, myocardial infarction and…
- Conditions
- Stable Angina, Ischemic Heart Disease Silent, ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction, In-stent Coronary Artery Restenosis
- Trial name
- Leaders Free (NCT01623180)
- Testing
- Biofreedom™ Drug Coated Stent (DCS), Gazelle™ Bare Metal Coronary Stent (BMS)
- Where
- Switzerland
- Volunteers
- 2,456 people
- Sponsor
- Biosensors Europe SA
Atherosclerosis
Integrated Biomarker And Imaging Study - 2
IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.
- Trial name
- NCT00268996
- Testing
- SB-480848
- Where
- 26 sites in Austria, Belgium and 9 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, Multi Vessel Coronary Artery Disease
Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass
To assess safety and feasibility of a coronary bypass created with Vascudyne Acellular Tissue Engineered Vessel (ATEV) with External Support Structure (ESS) in patients requiring multi vessel coronary artery bypass grafting…
- Trial name
- VCAB-2 (NCT07078370)
- Testing
- ATEV with ESS
- Where
- 4 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Vascudyne, Inc.
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX…
- Trial name
- NCT06991322
- Testing
- A-FLUX Reducer System
- Where
- 3 sites in Netherlands, Poland and 1 more
- Volunteers
- 30 people
- Sponsor
- VahatiCor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.